MENU

Primary Hyperoxaluria

Primary hyperoxaluria type 1 (PH1) is an inherited disease in which the lack of a particular liver enzyme causes the body to produce excess amounts of a substance called oxalate. This leads to a buildup of insoluble calcium oxalate, causing kidney failure and further organ damage for some patients in infancy and most patients by their mid-twenties.

PH1 is an ultra-rare orphan disease, defined as a disorder that affects less than 2,000 people. This devastating disease – which is often diagnosed in early childhood – is an inborn error of metabolism resulting in excessive oxalate production. Specifically, in PH1 there is a loss of function in the alanine-glyoxylate aminotransferase enzyme that metabolizes glyoxylate into glycine in the liver, resulting in its conversion to oxalate instead. Excess oxalate in PH1 patients is unable to be fully excreted by the kidneys leading to the formation of recurrent kidney stones and the deposition of calcium oxalate crystals in the kidneys and urinary tract. Renal damage is caused by a combination of tubular toxicity from oxalate, calcium oxalate deposition in the kidneys, and renal obstruction by calcium oxalate stones. Compromised kidney function exacerbates the disease as oxalate is released into systemic circulation potentially resulting in subsequent accumulation and crystallization in bones, eyes, skin, heart, and the central nervous system, leading to severe illness and death. About 50 percent of patients will have kidney failure by age 15, and about 80 percent will have end stage renal disease by age 30. Current treatment options are very limited, and include frequent renal dialysis as palliative care and combined organ transplantation of liver and kidneys as the only potentially curative option.

show more

ALN-GO1 for the Treatment of Primary Hyperoxaluria


Alnylam is developing ALN-GO1, a subcutaneously administered investigational RNAi therapeutic, for the treatment of PH1. ALN-GO1 targets the gene for glycolate oxidase (GO), an enzyme that works upstream of the defect in PH1 patients, and is designed to starve the pathway of substrate for oxalate production with the goal of preventing its associated pathology. ALN-GO1 utilizes Alnylam’s ESC-GalNAc conjugate technology, which enables subcutaneous dosing with increased potency and durability and a wide therapeutic index.

ALN-GO1 has been granted Orphan Drug Designation from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).

Please read the latest press releases and data presentations for ALN-GO1 here.

Less Content

Initial Results from Ongoing Phase 1/2 Study with ALN-GO1, in Development for the Treatment of Primary Hyperoxaluria Type 1

Initial Results from Ongoing Phase 1/2 Study with ALN-GO1, in Development for the Treatment of Primary Hyperoxaluria Type 1

We presented initial clinical data from ALN-GO1, an investigational RNAi therapeutic targeting glycolate oxidase (GO) for the treatment of Primary Hyperoxaluria Type 1 (PH1), at the 17th Congress of the International Pediatric Nephrology Association (IPNA), held September 20 – 24, 2016 in Iguaçu, Brazil.



Read More

Pre-Clinical Data with ALN-GO1, in Development for the Treatment of Primary Hyperoxaluria Type 1

Pre-Clinical Data with ALN-GO1, in Development for the Treatment of Primary Hyperoxaluria Type 1

We presented new pre-clinical data supporting the selection of a Development Candidate (DC) for ALN-GO1, an investigational RNAi therapeutic targeting glycolate oxidase (GO), also referred to as hydroxyacid oxidase 1 (HAO1), for the treatment of primary hyperoxaluria type 1 (PH1).  These data were presented at the 48th European Society of Paediatric Nephrology (ESPN) Annual meeting – held September 3 – 5, 2015, in Brussels – showing up to 99% silencing of the HAO1 mRNA and up to 98% mean reduction of urinary oxalate in animal models of PH1.



Read More

Alnylam R&D Day 2014 Webcast and Presentations

Alnylam R&D Day 2014 Webcast and Presentations

On December 12, we hosted an R&D Day in New York City. Alnylam management and key opinion leaders discussed the latest progress as well as plans for the future development of our RNAi therapeutics pipeline. At this event, we announced our pipeline growth strategy for development and commercialization of RNAi therapeutics across three Strategic Therapeutic Areas (STArs): Genetic Medicines, Cardio-metabolic Disease, and Hepatic Infectious Disease.



Read More